Voyager Therapeutics, Inc. (VYGR) Free cash flow 2016–2025
Voyager Therapeutics, Inc. (VYGR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$135.1MFY2025 · since FY2016: -$47.5M → -$135.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$135.1M | -617.2% |
| FY2024 | -$18.8M | -125.2% |
| FY2023 | $74.7M | +597.8% |
| FY2022 | -$15.0M | +72.8% |
| FY2021 | -$55.1M | +49.3% |
| FY2020 | -$108.8M | -365.7% |
| FY2019 | $40.9M | +302.8% |
| FY2018 | -$20.2M | +69.1% |
| FY2017 | -$65.3M | -37.5% |
| FY2016 | -$47.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice